Skip to main content

Catalyst Calendar

Tue, Oct 6, 2026

1 updates

7:05 AM

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

Trial StartTrial initiation Tue, Oct 6, 2026vikingtherapeutics.com

Mon, Sep 28, 2026

1 updates

4:30 PM

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

vikingtherapeutics.com

Thu, Sep 24, 2026

1 updates

7:05 AM

Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

vikingtherapeutics.com

Wed, Sep 23, 2026

1 updates

4:32 PM

Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes

vikingtherapeutics.com

Tue, Sep 22, 2026

1 updates

7:05 AM

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

Trial Results • Phase 2Topline results Tue, Sep 22, 2026, 8:00 AM ETvikingtherapeutics.com

Wed, Sep 2, 2026

1 updates

4:05 PM

Viking Therapeutics to Participate at Upcoming Investor Conferences

vikingtherapeutics.com